The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Disclosed are aminocoumarin compounds, pharmaceutical compositions containing aminocoumarin compounds, and methods of their use, e.g., in the treatment of a Gram-negative bacterial infection.

A quaternary ammonium salt comprising a chromophore constituent, a tertiary amine cation constituent connected to the para-position of the chromophore constituent via a methylene linkage, and a borate anion constituent, wherein chromophore constituent is a 3-ketocoumarin constituent or a benzophenone constituent. Also, a photobase-redox initiating system comprising the quaternary ammonium salt and a peroxide.

A quaternary ammonium salt comprising a chromophore constituent, a tertiary amine cation constituent connected to the para-position of the chromophore constituent via a methylene linkage, and a borate anion constituent, wherein chromophore constituent is a 3-ketocoumarin constituent or a benzophenone constituent. Also, a photobase-redox initiating system comprising the quaternary ammonium salt and a peroxide.

A method for synthesizing (RS)-Warfarin comprising preparing a liquid mixture, wherein the liquid mixture comprises trihexyltetradecylphosphonium bromide, methyl salicylate, acetyl chloride, benzaldehyde, and acetone. The method may further comprise incubating the liquid mixture at a temperature between 20° C. and 30° C. for a time duration between 26 and 34 minutes, and forming (RS)-Warfarin by adding water to the incubated liquid mixture with a volume ratio (water:incubated liquid mixture) between 1:1 and 1.5:1.

A method for synthesizing (RS)-Warfarin comprising preparing a liquid mixture, wherein the liquid mixture comprises trihexyltetradecylphosphonium bromide, methyl salicylate, acetyl chloride, benzaldehyde, and acetone. The method may further comprise incubating the liquid mixture at a temperature between 20° C. and 30° C. for a time duration between 26 and 34 minutes, and forming (RS)-Warfarin by adding water to the incubated liquid mixture with a volume ratio (water:incubated liquid mixture) between 1:1 and 1.5:1.

O-substituted hydroxamic acids with carbon-based leaving groups as HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions also are disclosed.

O-substituted hydroxamic acids with carbon-based leaving groups as HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions also are disclosed.

A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a thrombolytic drug and the matrix component includes a hyaluronan or derivative thereof, the matrix component having a viscosity greater than 10 mPa.Math.s.

Disclosed are aminocoumarin compounds, pharmaceutical compositions containing aminocoumarin compounds, and methods of their use, e.g., in the treatment of a Gram-negative bacterial infection.